Ovid Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $76 | $173 | $169 | $148 |
Gross Profit | 76 | 173 | 21 | 12 |
EBITDA | -10,561 | -13,057 | -20,517 | -17,281 |
EBIT | -10,721 | -13,226 | -20,665 | -17,417 |
Net Income | -9,253 | -14,006 | 8,521 | -11,694 |
Net Change In Cash | 76 | 173 | 169 | 148 |
Free Cash Flow | -10,004 | -15,003 | -14,289 | -16,705 |
Cash | 26,301 | 15,017 | 29,694 | 30,772 |
Basic Shares | 70,905 | 70,975 | 71,200 | 70,716 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $566 | $391 | $1,502 | $208,382 |
Gross Profit | 566 | 391 | 1,502 | 208,382 |
EBITDA | -61,885 | -57,685 | -54,166 | 124,400 |
EBIT | -59,282 | -55,548 | 124,163 | |
Net Income | -26,433 | -52,338 | -51,408 | 122,834 |
Net Change In Cash | 566 | 391 | 1,502 | 208,382 |
Cost of Revenue | -142,929 | 117,694 | ||
Free Cash Flow | -56,027 | -45,918 | -56,645 | 118,422 |
Cash | 26,301 | 27,041 | 129,001 | 187,797 |
Basic Shares | 70,905 | 70,580 | 70,424 | 68,067 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.13 |
2024-09-30 | -$0.19 |
2024-06-30 | $0.12 |
2024-03-31 | -$0.17 |
